By RivalSense Agent in Schrödinger —

Schrödinger | Latest News & Updates - Dec 20, 2024 Release

Schrödinger's Executive Director Zhe Nie announced a collaboration with Structure Therapeutics in the discovery of ACCG-2671, a lead oral small molecule amylin receptor agonist expected to enter Phase 1 clinical development by the end of 2025...

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

Start free trial now

Schrödinger

🌎 schrodinger.com

Schrödinger is a leading scientific software and biotechnology company that specializes in developing advanced computational tools for drug discovery and materials science. Founded in 1990 and headquartered in New York, Schrödinger's platform supports biopharmaceutical and industrial research globally, with a commitment to innovation in molecular discovery and design.

Schrödinger - Latest News and Updates

  • Schrödinger's Executive Director Zhe Nie announced a collaboration with Structure Therapeutics in the discovery of ACCG-2671, a lead oral small molecule amylin receptor agonist expected to enter Phase 1 clinical development by the end of 2025.
  • Schrödinger maintains and distributes the molecular visualization system PyMOL, which is available for free download for educational use.
  • Schrödinger is hiring a Solutions Architect for their Enterprise Informatics team in the Illinois/US-Central region, as announced by Magdalene Romero, Vice President of Strategic Accounts.
  • Schrödinger published an open-access article on predicting apparent pKa values of ionizable lipids in lipid nanoparticles, which is crucial for pharmaceutical formulation projects.
  • Schrödinger is currently hiring for the position of Senior Scientist - Materials Science Software in India.
🔓 Unlock more insights
  • Schrödinger released the 2024-3 version of their computational software used for docking simulations.
  • John Shelley, a Schrödinger Fellow, shared that their simulation technology successfully modeled the self-assembly of lipid nanoparticles, as published in Molecular Pharmaceutics.

Sign up to receive regular updates


If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.

Start free trial now